We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Test Distinguishes Types of Malaria

By LabMedica International staff writers
Posted on 08 Sep 2017
Print article
Image: The dual-band (histidine-rich protein-2/pan-lactate dehydrogenase [HRP2/pLDH]) rapid diagnostic test (RDT) to differentiate uncomplicated from severe malaria (Photo courtesy of Standard Diagnostics).
Image: The dual-band (histidine-rich protein-2/pan-lactate dehydrogenase [HRP2/pLDH]) rapid diagnostic test (RDT) to differentiate uncomplicated from severe malaria (Photo courtesy of Standard Diagnostics).
Malaria is a leading cause of death for children living in Sub-Saharan Africa and many children in rural areas seek care at local community health clinics, but these clinics lack reliable tests to distinguish severe and uncomplicated malaria.

The diagnosis of malaria was traditionally was made using Giemsa-stained blood smears, but rapid diagnostic tests are now widely used. The potential of using a low-cost, routinely available rapid diagnostic test to distinguish between severe and uncomplicated malaria in children has been investigated.

Scientists at the University of North Carolina at Chapel Hill (NC, USA) and their colleagues performed a prospective, observational cohort study, to assess the accuracy of a dual-band (histidine-rich protein-2/pan-lactate dehydrogenase [HRP2/pLDH]) rapid diagnostic test (RDT) to differentiate uncomplicated from severe malaria. A total of 2,678 children with fever from Western Uganda underwent testing for malaria using a rapid diagnostic test.

The scientist found that nearly half tested positive for malaria and 83 satisfied criteria for severe malaria. The sensitivity and specificity of the rapid diagnostic test for detecting severe malaria was 97.6% and 75.6%, respectively. The test was especially sensitive for children less than five years of age. Knowing when a child is suffering from severe malaria allows for a referral to a health center better equipped to handle the disease's grave manifestations. An HRP2+/pLDH+ result was significantly more sensitive (97.6% versus 68.7%) for the detection of severe malaria compared to algorithms that incorporate screening for danger signs.

The authors concluded that a positive dual-antigen (HRP2/pLDH) RDT has higher sensitivity than the use of clinical manifestations to detect severe malaria, making it a promising tool in the triage of children with malaria in low-resource settings. Ross Boyce, MD, MSc, the lead author of the study said, “Rapid diagnostic tests have been around for a while, and are generally considered standard of care in most malaria-endemic settings. However, what we've done is show that these relatively simple tests can be used in new ways to provide important information beyond just a positive or negative result.” The study was published on August 24, 2017, in the journal Clinical Infectious Diseases.

Related Links:
University of North Carolina at Chapel Hill

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Toxoplasma Gondii Immunoassay
Toxo IgM AccuBind ELISA Kit
New
Respiratory Bacterial Panel
Real Respiratory Bacterial Panel 2

Print article

Channels

Molecular Diagnostics

view channel
Image: The Mirvie RNA platform predicts pregnancy complications months before they occur using a simple blood test (Photo courtesy of Mirvie)

RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms

Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Schematic illustration of the chip (Photo courtesy of Biosensors and Bioelectronics, DOI: https://doi.org/10.1016/j.bios.2025.117401)

Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples

Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.